Medical monitoring

MobileHelp® Healthcare Features Webinar on New CPT Codes for Remote Patient Monitoring Reimbursement

Retrieved on: 
Tuesday, June 11, 2019
Articles, Health informatics, Health, Technology, Telemedicine, Medical monitoring, Remote patient monitoring, Telehealth, eHealth, Connected health

BOCA RATON, Fla., June 11, 2019 /PRNewswire/ -- MobileHelp Healthcare , aleader inhealthcare technology solutions,is hosting a new webinar titled "Understanding CMS Reimbursement Opportunities for Remote Patient Monitoring," aimed at helping healthcare providerswho want to improve patient care and optimize new reimbursement options through utilization of a remote patient monitoring (RPM) program.

Key Points: 
  • BOCA RATON, Fla., June 11, 2019 /PRNewswire/ -- MobileHelp Healthcare , aleader inhealthcare technology solutions,is hosting a new webinar titled "Understanding CMS Reimbursement Opportunities for Remote Patient Monitoring," aimed at helping healthcare providerswho want to improve patient care and optimize new reimbursement options through utilization of a remote patient monitoring (RPM) program.
  • Registration for the webinar is available free of charge on the MobileHelp Healthcare website , and spots are still available.
  • MobileHelpHealthcare is a division of MobileHelp, a leading provider of mobile Personal Emergency Response Systems (PERS) and remote patient monitoring technology.
  • MobileHelp Healthcare provides healthcare organizations with a full range of telehealth product and service solutions designed to achieve better patient outcomes through enhanced oversight and reduced readmission.

$21.8Bn Glucose Monitoring Devices Market, 2027: Global Analysis & Forecasts by Product, End-user and Geography - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 11, 2019
Health, Medical devices, Diabetes, Medicine, Clinical medicine, Medical tests, Medical monitoring, Blood tests, Blood glucose monitoring, Diabetes, Glucose, Glucose meter, Insulin pump

The "Glucose Monitoring Devices Market to 2027 - Global Analysis and Forecasts by Product; End User and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glucose Monitoring Devices Market to 2027 - Global Analysis and Forecasts by Product; End User and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The global glucose monitoring devices market is expected to reach US$ 21.8Bn in 2027 from US$ 12.6Bn in 2018.
  • However, the factors restraining the market growth are high cost of glucose monitoring devices.
  • Global glucose monitoring devices market was segmented by product and end user.

Masimo Announces FDA Clearance of Neonatal Indication for O3® Regional Oximetry

Retrieved on: 
Monday, June 10, 2019
Surgery, Health, Biotechnology, Hospitals, Medical devices, FDA, General Health, Health, Medicine, Masimo, Medical equipment, Medical monitoring, Pulse oximetry, Food and Drug Administration, Joe Kiani

Masimo (NASDAQ: MASI) announced today that O3 Regional Oximetry has received FDA clearance for use on neonatal and infant patients (

Key Points: 
  • Masimo (NASDAQ: MASI) announced today that O3 Regional Oximetry has received FDA clearance for use on neonatal and infant patients (
  • O3 is available as a Masimo Open Connect (MOC-9) module for the Root Patient Monitoring and Connectivity Platform.
  • Using Root in combination with Masimo Patient SafetyNet or Iris Gateway, monitoring data from O3 can be automatically charted in electronic medical records (EMRs).
  • Published clinical studies on pulse oximetry and the benefits of Masimo SET can be found on our website at http://www.masimo.com .

New Recommendations for Time-in-Range Targets During Continuous Glucose Monitoring Presented Today at the ADA's Scientific Sessions

Retrieved on: 
Saturday, June 8, 2019
Medicine, Diabetes, Clinical medicine, Endocrine system, Blood tests, Medical monitoring, RTT, Blood glucose monitoring, Continuous glucose monitor, Blood sugar level, Glucose, Glycemic

Thegroup's recommendations are also published online today as a manuscript titled, "Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations from the International Consensus on Time-in-Range" in Diabetes Care .

Key Points: 
  • Thegroup's recommendations are also published online today as a manuscript titled, "Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations from the International Consensus on Time-in-Range" in Diabetes Care .
  • Continuous Glucose Monitoring (CGM) provides people living with diabetes real-time readings of their blood glucose levels via a sensor that is inserted under the skin.
  • The technology offers measurement of current glucose levels and insight on the direction and rate of change in glucose levels.
  • One potential reason is a lack of clear and agreed upon glycemic targets that diabetes care teams and people with diabetes can work towards.

New Data Show Use of Abbott's FreeStyle® Libre System Significantly Reduces HbA1c Levels in People Living with Type 2 Diabetes

Retrieved on: 
Saturday, June 8, 2019
Diabetes, Medicine, Clinical medicine, Endocrine diseases, Blood tests, Medical monitoring, RTT, Diabetes management, Blood glucose monitoring, Glycated hemoglobin, Type 2 diabetes

For people managing diabetes, the goal of reaching normal A1c levels is one of the critical success measurements because it is correlated with long-term health outcomes.

Key Points: 
  • For people managing diabetes, the goal of reaching normal A1c levels is one of the critical success measurements because it is correlated with long-term health outcomes.
  • For the U.S. version of FreeStyle Libre system, the Indications and Important Safety Information is below.
  • The FreeStyle Libre 14 day system is not approved for pregnant women, persons on dialysis, or critically-ill population.
  • 2Krger, J., Fasching, P, Hanaire, H, Meta-Analysis of Three, Real-World, Chart Review Studies to Determine the Effectiveness of FreeStyle Libre Flash Glucose Monitoring System on HbA1c in Adults with Type 2 Diabetes.

Senseonics to Participate in the Raymond James Life Sciences and MedTech Conference

Retrieved on: 
Tuesday, June 4, 2019
Technology, Data management, Software, Health, Medical devices, Mobile, Wireless, Diabetes, Medicine, Continuous glucose monitor, Medical monitoring, Blood tests, Clinical medicine, Health, Blood glucose monitoring, CGM, Medtech, Zimmer Biomet Robotics

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the company plans to participate in the upcoming Raymond James Life Sciences and MedTech Conference in New York, NY.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the company plans to participate in the upcoming Raymond James Life Sciences and MedTech Conference in New York, NY.
  • Management is scheduled to present Tuesday, June 18, 2019 at 4:10pm ET.
  • Interested parties may access a live and recorded webcast of the presentation on the Investor Relations section of the companys website at www.senseonics.com .
  • Senseonics' CGM systems, Eversense and Eversense XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor.

Diabetes Diagnostics in 2019: Global Market Analysis, Trends and Forecasts Through 2015-2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 4, 2019
Health, Diabetes, Medicine, Medical tests, Clinical medicine, Blood tests, Blood glucose monitoring, Medical monitoring, Glucose

Quality Products at Low Prices: Mantra for Success in the Marketplace

Key Points: 

Quality Products at Low Prices: Mantra for Success in the Marketplace
Glucose Monitoring through Smartphone Apps: The Latest Breakthrough
Bar-Illan University of Israel's Research for Non-invasive, Wearable Glucose Testing Device

Caretaker Medical Adds Continuous Beat-by-Beat Blood Pressure & Wireless Vitals to HealthSaaS Remote Patient Monitoring Platform

Retrieved on: 
Thursday, May 30, 2019
Medicine, Articles, Health, Health informatics, Medical monitoring, Anesthesia, Intensive care medicine, Monitoring, Nanomedicine, Telehealth, Vital signs, Remote patient monitoring

CHARLOTTESVILLE, Va.and BEAVERTON Ore., May 30, 2019 /PRNewswire/ --Caretaker Medical, maker of the Wireless Caretaker Finger-Cuff Patient Monitoring Platform for Continuous Non-Invasive Blood Pressure ("CNIBP") & Wireless Vital Signs, today announced seamless integration with the HealthSaaS HIPAA-Compliant Cloud Platform for Remote Patient Monitoring, Telehealth, and Hospital-to-Home Patient Engagement.

Key Points: 
  • CHARLOTTESVILLE, Va.and BEAVERTON Ore., May 30, 2019 /PRNewswire/ --Caretaker Medical, maker of the Wireless Caretaker Finger-Cuff Patient Monitoring Platform for Continuous Non-Invasive Blood Pressure ("CNIBP") & Wireless Vital Signs, today announced seamless integration with the HealthSaaS HIPAA-Compliant Cloud Platform for Remote Patient Monitoring, Telehealth, and Hospital-to-Home Patient Engagement.
  • "We are excited to have our FDA-Cleared Caretaker wireless patient monitor streaming continuous "Beat-by-Beat" Blood Pressure and Vital Signs to the HealthSaaS Remote Monitoring Cloud," said Jeff Pompeo, Caretaker Medical's President & CEO.
  • "Adding Caretaker continuous blood pressure monitoring to the HealthSaaS connected device portfolio, is a significant step forward in our hospital-to-home strategy for cardiology patients," said Frank Ille, CEO of HealthSaaS.
  • The Caretaker wireless CNIBP and Vital Signs Monitor is FDA Cleared, CE-Mark certified, and available immediately for use with the HIPAA-Compliant HealthSaaS Remote Monitoring Platform.

Global Continuous Glucose Monitoring Device (CGM) Markets to 2023: Anticipating a CAGR of 21.25% - ResearchAndMarkets.com

Retrieved on: 
Monday, May 27, 2019
Health, Medical devices, Diabetes, Medicine, Medical specialties, Clinical medicine, Eli Lilly and Company, Medical monitoring, Insulin pump, Blood glucose monitoring, Continuous glucose monitor, Glucose, Insulin, Monitoring, Dexcom

5.

Key Points: 
  • 5.
  • Global Continuous Glucose Monitoring Devices Market: Growth and Forecast
    6.
  • Global Continuous Glucose Monitoring Devices Market: Segment Analysis
    6.1 Global Continuous Glucose Monitoring Devices Market Size, By Component: Breakdown (%)
    6.1.1 Global Continuous Glucose Monitoring Devices Market Size, By Component, 2017 (%)
    6.1.2 Global Continuous Glucose Monitoring Devices Market Size, By Component, 2023 (%)
    6.2 Global Transmitter & Receiver Component Market Size, By Value (2013-2023)
    6.3 Global Sensor Component Market Size, By Value (2013-2023)
    6.4 Global Integrated Insulin Pump Component Market Size, By Value (2013-2023)
    6.5 Global Continuous Glucose Monitoring Device Market Size, By Demographics: Breakdown(%)
    6.5.1 Global Continuous Glucose Monitoring Devices Market Size, By Demographics, 2017 (%)
    6.5.2 Global Continuous Glucose Monitoring Devices Market Size, By Demographics, 2023 (%)
    6.6 Global Pediatric patient Market Size, By Value (2013-2023)
    6.7 Global Adult patient Market Size, By Value (2013-2023)
    6.8 Global Continuous Glucose Monitoring Device Market Size, By End User: Breakdown (%)
    6.8.1 Global Continuous Glucose Monitoring Devices Market Size, By End User, 2017 (%)
    6.8.2 Global Continuous Glucose Monitoring Devices Market Size, By End User, 2023 (%)
    6.9 Global Homecare Continuous Glucose Monitoring Device Market Size, By Value (2013-2023)
    6.10 Global Hospital Continuous Glucose monitoring Device Market Size, By Value (2013-2023)
    7.
  • Global Continuous Glucose Monitoring Devices Market: Regional Analysis
    7.1 Global Continuous Glucose Monitoring Devices Market Size, By Region: Breakdown (%)
    7.2 North America Continuous Glucose Monitoring Devices Market: Growth and Forecast
    7.3 North America Continuous Glucose Monitoring Devices Market: Country Analysis (US, Canada)
    7.4 Europe Continuous Glucose Monitoring Devices Market: Growth and Forecast
    7.5 Europe Continuous Glucose Monitoring Devices Market: Country Analysis (UK, Germany)
    7.6 APAC Continuous Glucose Monitoring Devices Market: Growth and Forecast
    7.7 APAC Continuous Glucose Monitoring Devices Market: Country Analysis (Japan, India, China)
    7.8 ROW Continuous Glucose Monitoring Devices Market: Growth and Forecast
    7.9 ROW Continuous Glucose Monitoring Devices Market: Country Analysis (Brazil)

Senseonics to Participate in the Guggenheim MedTech Disruptors Summit

Retrieved on: 
Tuesday, May 21, 2019
Health, Medical devices, Diabetes, Managed care, Medicine, Medical technology, Blood tests, Medical monitoring, Continuous glucose monitor, Clinical medicine, Blood glucose monitoring, Zimmer Biomet Robotics, Medtech, CGM, Diabetes

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the company plans to participate in the upcoming Guggenheim MedTech Disruptors Summit in New York, NY.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the company plans to participate in the upcoming Guggenheim MedTech Disruptors Summit in New York, NY.
  • Interested parties may access a live and recorded webcast of the presentation on the Investor Relations section of the companys website at www.senseonics.com .
  • From its inception, Senseonics has been advancing the integration of novel, fluorescence sensor technology with smart wearable devices.
  • The Eversense XL CGM System received CE mark for up to 180 days of continuous use and is available in Europe.